Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Smith

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
American Journal of Preventive Medicine|June 21, 2016
Community Health Workers as Support for Sickle Cell CareLewis L Hsu, Nancy S Green, E Donnell Ivy, et al.
Pediatric Blood & Cancer|September 12, 2022
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease centerMonica L Hulbert, Deepa Manwani, Emily Riehm Meier, et al.
Clinical Trials (London, England)|March 30, 2013
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesCarlton D Dampier, Wally R Smith, Carrie G Wager, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 30, 2021
Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathiesLaura Breda, Valentina Ghiaccio, Naoto Tanaka, et al.
The Journal of Pediatrics|April 16, 2002
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial strokeDouglas J Scothorn, Cynthia Price, Daniel Schwartz, et al.
Health and Quality of Life Outcomes|June 14, 2017
Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease ModuleJulie A Panepinto, J Paul Scott, Oluwakemi Badaki-Makun, et al.
Blood|August 2, 2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in childrenDavid C Brousseau, J Paul Scott, Oluwakemi Badaki-Makun, et al.
Pediatric Blood & Cancer|March 7, 2025
Engaging Parents of Children With Sickle Cell Disease in Shared Decision-Making for Hydroxyurea: The ENGAGE-HU StudyAimee K Hildenbrand, Constance A Mara, Bridget Murphy, et al.
JMIR Research Protocols|May 21, 2021
Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled TrialAnna M Hood, Heather Strong, Cara Nwankwo, et al.
Annals of the American Thoracic Society|August 31, 2019
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop ReportA Parker Ruhl, S Christy Sadreameli, Julian L Allen, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
American Journal of Preventive Medicine|June 21, 2016
Community Health Workers as Support for Sickle Cell CareLewis L Hsu, Nancy S Green, E Donnell Ivy, et al.
Pediatric Blood & Cancer|September 12, 2022
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease centerMonica L Hulbert, Deepa Manwani, Emily Riehm Meier, et al.
Clinical Trials (London, England)|March 30, 2013
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesCarlton D Dampier, Wally R Smith, Carrie G Wager, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 30, 2021
Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathiesLaura Breda, Valentina Ghiaccio, Naoto Tanaka, et al.
The Journal of Pediatrics|April 16, 2002
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial strokeDouglas J Scothorn, Cynthia Price, Daniel Schwartz, et al.
Health and Quality of Life Outcomes|June 14, 2017
Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease ModuleJulie A Panepinto, J Paul Scott, Oluwakemi Badaki-Makun, et al.
Blood|August 2, 2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in childrenDavid C Brousseau, J Paul Scott, Oluwakemi Badaki-Makun, et al.
Pediatric Blood & Cancer|March 7, 2025
Engaging Parents of Children With Sickle Cell Disease in Shared Decision-Making for Hydroxyurea: The ENGAGE-HU StudyAimee K Hildenbrand, Constance A Mara, Bridget Murphy, et al.
JMIR Research Protocols|May 21, 2021
Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled TrialAnna M Hood, Heather Strong, Cara Nwankwo, et al.
Annals of the American Thoracic Society|August 31, 2019
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop ReportA Parker Ruhl, S Christy Sadreameli, Julian L Allen, et al.
Pageof 14